Pharmaceutical Report Library l Report Store l Pharma Intelligence

Zyvox

Pfizer developed Zyvox (linezolid) as the first oxazolidinone antimicrobial agent. The drug gained its first regulatory approval for the treatment of complicated skin and skin structure infections (cSSSI) in the US market in 2000.

June 19, 2015

Find out more

Zytiga

Zytiga (abiraterone acetate; Johnson & Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates involved in testosterone synthesis.

January 18, 2018

Find out more

Zyprexa

Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors.

April 9, 2018

Find out more

Zykadia

Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK).

August 30, 2018

Find out more

Zydelig

Zydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in decreased phosphorylation Akt and other downstream effectors, an increase in poly (ADP-ribose) polymerase and caspase cleavage, and an induction of apoptosis.

January 31, 2019

Find out more

Zybrestat

Zybrestat (fosbretabulin tromethamine; Mateon Therapeutics) is a water-soluble prodrug of cis-combretastatin A4, originally isolated from the African bush willow (Combretum caffrum).

August 17, 2017

Find out more

Zulresso

Zulresso is SAGE Therapeutics’ proprietary intravenous formulation of brexanolone, which is an allosteric modulator of both synaptic and extra-synaptic GABA-A receptors.

March 29, 2019

Find out more

Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey

$599.00

Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.

May 13, 2014

Find out more

Zontivity

Zontivity (vorapaxar; Merck & Co) gained US and EU approval for the reduction of thromboembolic

events in secondary-prevention patients with a history of myocardial infarction (MI).

April 14, 2016

Find out more

Zoladex

Zoladex (goserelin; AstraZeneca/TerSera Therapeutics) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”

January 18, 2018

Find out more

Zinbryta

Zinbryta is a humanized monoclonal antibody that selectively binds to the alpha chain (cluster of differentiation [CD]25) of the interleukin-2 receptor on activated T cells to prevent the immunoactivation of MS.

November 24, 2017

Find out more

Zevalin

Zevalin (ibritumomab tiuxetan; Acrotech Biopharma/Mundipharma) is an intravenous radioactive agent consisting of the murine monoclonal antibody (MAb) ibritumomab, which is covalently linked to the chelator tiuxetan.

January 30, 2019

Find out more

Zetia Franchise

Multiple combination products based on the same active compound are known as a drug franchise. Franchises exist to give physicians, as well as patients, different treatment choices and to help with issues such as pill burden and compliance.

June 22, 2018

Find out more

Zepsyre

Zepsyre (lurbinectedin; PharmaMar/Chugai) is a novel synthetic agent derived from the marine-derived alkaloid trabectedin that inhibits the transcription process.

August 17, 2017

Find out more

Zepatier

Zepatier is a once-daily, fixed-dose combination of Merck & Co’s second-generation protease inhibitor, grazoprevir, and the company’s NS5A inhibitor, elbasvir.

November 6, 2017

Find out more

Zeltherva

Zeltherva’s (galinpepimut-S; SELLAS Life Sciences Group) larger target patient population gives it more commercial potential than other drugs being positioned towards the maintenance setting.

July 6, 2017

Find out more

Zelboraf

Zelboraf (vemurafenib; Roche/Chugai/Daiichi Sankyo) is an orally available agent that selectively targets the BRAF mutation. BRAF is part of the mitogen-activated protein kinase (MAPK) signal transduction pathway, which is critical in tumor cell proliferation.

May 23, 2018

Find out more

Zelapar

Zelapar (selegiline; Valeant) is a novel rapidly disintegrating tablet formulation of the monoamine oxidase B (MAO-B) inhibitor selegiline.

October 24, 2014

Find out more

Zejula

Zejula (niraprib; Tesaro/Takeda) is a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP). PARP inhibitors block the activity of PARP, an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death.

August 17, 2017

Find out more

Zeftera

Zeftera (ceftobiprole medocaril; Basilea Pharmaceutica) is a novel intravenous broad-spectrum fifth-generation cephalosporin.

June 19, 2015

Find out more

Zanubrutinib

Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK), developed to be more selective with less off-target effects than Imbruvica (ibrutinib; AbbVie/Johnson & Johnson). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies.

January 31, 2019

Find out more

Zaltrap

Zaltrap is a human recombinant fusion protein comprising segments of the human VEGFRs 1 and 2
and the Fc portion of the human immunoglobulin G1 (Tang et al., 2008).

January 19, 2016

Find out more

Zafatek

Zafatek (trelagliptin; Takeda) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.

November 7, 2017

Find out more

Yonsa

Yonsa (Churchill Pharmaceuticals) is an oral, ultramicrosize tablet formulation of abiraterone acetate that inhibits 17 alpha-hydroxylase (CYP17). The CYP17 family of enzymes catalyze the hydroxylation of intermediates involved in testosterone synthesis, a common driver of prostate cancer genesis and recurrence.

January 18, 2018

Find out more

Ygalo

Ygalo (melphalan-flufenamide; Oncopeptides) is a cytotoxic alkylating agent that consists of melphalan conjugated to phenylalanine

August 9, 2018

Find out more

Yescarta

Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.

January 30, 2019

Find out more

Yervoy

Yervoy (ipilimumab; Bristol-Myers Squibb/Ono Pharmaceutical) is an intravenous fully humanized immunoglobulin-G1 monoclonal antibody that targets human cytotoxic T-lymphocyte-associated protein-4 (CTLA-4).

May 23, 2018

Find out more

Xyntha

Xyntha is a recombinant factor VIII (rfVIII) therapy approved for the treatment of hemophilia A.

Although Pfizer has taken steps to enhance the product by improving the manufacturing processes

and developing an application device for the therapy, Xyntha’s target patient population will be

reduced by competitor therapies approved for prophylactic use.

May 4, 2018

Find out more

Xultophy

Xultophy ([insulin degludec + liraglutide]; Novo Nordisk) is a once-daily, injectable combination product comprising a fixed ratio of Novo Nordisk’s long-lasting basal insulin Tresiba (insulin degludec) and glucagon-like peptide-1 receptor agonist Victoza (liraglutide) for the treatment of type 2 diabetes.

November 7, 2017

Find out more

Xtandi

Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits binding of the androgens to the AR, inhibits AR nuclear translocation, and inhibits association of the AR with DNA.

January 18, 2018

Find out more

Report library

Zyvox

Zytiga

Zyprexa

Zykadia

Zydelig

Zybrestat

Zulresso

Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey

Zontivity

Zoladex

Zinbryta

Zevalin

Zetia Franchise

Zepsyre

Zepatier

Zeltherva

Zelboraf

Zelapar

Zejula

Zeftera

Zanubrutinib

Zaltrap

Zafatek

Yonsa

Ygalo

Yescarta

Yervoy

Xyntha

Xultophy

Xtandi